At the American Thoracic Society meeting, Dr Kirsten Almberg discussed the rise of black lung, lung cancer, and chronic obstructive pulmonary disease (COPD) in US coal miners. Here, she reiterates the results of two studies assessing mortality in US-based coal miners and the further work that needs to be done to better understand the health risks to US coal miners and develop strategies to reduce health risk.
1. Please describe what health risks exist for US coal miners? (0:05)
2. You recently published two adjacent studies assessing mortality in US-based coal miners – please outline how you investigated this? (1:18)
3. What did these studies demonstrate in terms of changes over time in disease mortality from black lung, lung cancer and COPD? (3:30)
4. Which factors underline or are proposed to underline the increased mortality from these diseases? (5:38)
5. What further work needs to be done to better understand the health risks to US coal miners and develop strategies to reduce health risk? (7:26)
Share this Video
Related Videos In COPD
Air pollution and respiratory diseases: Claudia Traidl-Hoffmann, EAACI 2023
Air pollution has been linked to exacerbating and causing symptoms associated with respiratory diseases, particularly impacting patients with asthma, COPD and allergic disease. touchRESPIRATORY were delighted to speak with Prof. Claudia Traidl-Hoffmann (University in Augsburg, Germany) around the symptoms associated with exposure to air pollution, the impact of air pollution on existing respiratory conditions and […]
BOREAS: phase 3 study of dupilumab in COPD: Klaus F. Rabe, ATS 2023
The phase 3 BOREAS study (NCT03930732) investigated the efficacy and safety of dupilumab for the treatment of chronic obstructive pulmonary disease with type 2 inflammation. It was a pleasure to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the aims, design, inclusion criteria and findings from the phase 3 study and the […]
Dupilumab: an investigational monoclonal antibody for COPD: Klaus F. Rabe, ATS 2023
Dupilumab is an investigational monoclonal antibody that mitigates type 2 inflammation by blocking IL-4 and IL-13 receptors in patients with COPD. We were delighted to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the unmet needs in the treatment of COPD, the association between type 2 inflammation and COPD exacerbations and the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!